Pacer Advisors
EPZM

Pacer Advisors’s Epizyme, Inc EPZM Stock Holding History

Pacer Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,390
Closed -$56K – 1601
2021
Q1 		$56K Buy
6,390
+882
+16% +$9.13K ﹤0.01% 1430
2020
Q4 		$60K Buy
5,508
+1,409
+34% +$17.4K ﹤0.01% 1402
2020
Q3 		$49K Buy
+4,099
New +$54.9K ﹤0.01% 1306
2018
Q4 		– Sell
-4,441
Closed -$47K – 1116
2018
Q3 		$47K Buy
+4,441
New +$50.7K ﹤0.01% 1145
2018
Q1 		– Sell
-1,100
Closed -$14K – 1152
2017
Q4 		$14K Buy
+1,100
New +$16K ﹤0.01% 1125

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Pacer Advisors's EPZM Position: Q2 2021 in Review

Pacer Advisors sold out of Epizyme, Inc (EPZM) in Q2 2021, closing a stake of 6,390 shares — an estimated $56K sold.

Pacer Advisors first reported a position in EPZM in Q4 2017 and held it in 5 quarters. The position peaked at $60K in Q4 2020. 127 funds tracked by Wall St. Rank hold EPZM as of Q2 2021.

  • Pacer Advisors reported no remaining Epizyme, Inc position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 6,390 Epizyme, Inc shares in Q2 2021, an estimated $56K.
  • Pacer Advisors first reported a position in Epizyme, Inc in Q4 2017 and held it in 5 quarters.
  • Pacer Advisors's Epizyme, Inc position peaked at $60K in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.